Gritstone Jumps Into COVID-19 Vaccine Race, Eyeing Mutant Strains
Potentially Resistant Strains Raise Worries
The company is developing a vaccine with both adenoviral and mRNA technology that could potentially overcome resistance mutations on the SARS-CoV-2 spike protein.
You may also be interested in...
Pfizer and BioNTech sent in Phase I data for a third dose of BNT162b2 to support future licensure, Gritstone bio will work with CEPI to develop its second-generation vaccine in South Africa and other areas, and Roche Genentech expects a shortage of the drug Actemra to last for several weeks amid a surge in cases.
Gritstone will supply the same type of prime-boost vaccine technology it is applying to SARS-CoV-2, and Gilead will supply its own antigens, with the goal of curing HIV.
The company said data show a lower overall infection rate and no symptomatic infections among participants receiving the drug, compared with placebo.